{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T06:39:44Z","timestamp":1765435184528,"version":"3.46.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Digit. Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      This multi-center, parallel-group randomized controlled trial evaluated the app-based intervention\n                      <jats:italic>mebix<\/jats:italic>\n                      , developed by Vision2b GmbH in Germany, for people with type 2 diabetes compared to a placebo app.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A total of 153 participants were randomized in a 1:1 ratio to either intervention or control group, with allocation concealment ensured by a minimization procedure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After six months, participants using\n                      <jats:italic>mebix<\/jats:italic>\n                      achieved a statistically significant reduction in HbA1c levels by 0.82 percentage points (95% confidence interval: \u22121.20, \u22120.48,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). This reduction was greater than in the control group (mean difference: 0.24 percentage points, 95% confidence interval: \u22120.44, 0.09).\n                      <jats:italic>mebix<\/jats:italic>\n                      users further experienced greater weight loss, lower diabetes-related distress, and reduced depression severity. Adherence to the app was high, with more than 75% of participants using\n                      <jats:italic>mebix<\/jats:italic>\n                      throughout the study period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings indicate that the digital approach can meaningfully improve both glycemic control and psychological well-being in people with type 2 diabetes, supporting its potential integration into routine care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.evamebix.de<\/jats:ext-link>\n                      , identifier DRKS00025719, DRKS00032395.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fdgth.2025.1644612","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T06:36:05Z","timestamp":1765434965000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Randomized controlled trial to evaluate an app-based multimodal digital intervention for people with type 2 diabetes in comparison to a placebo app"],"prefix":"10.3389","volume":"7","author":[{"given":"Lena","family":"Roth","sequence":"first","affiliation":[]},{"given":"Maxi Pia","family":"Bretschneider","sequence":"additional","affiliation":[]},{"given":"Peter E. H.","family":"Schwarz","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"B1","volume-title":"IDF Diabetes Atlas 2025","year":"2025"},{"key":"B2","volume-title":"Diabetes in Germany\u2014National Diabetes Surveillance Report 2019","year":"2019"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1388189","DOI":"10.3389\/fepid.2025.1388189","article-title":"Future prevalence of type 2 diabetes in Germany: a projection until 2040 including incidence trends observed during the SARS-CoV-2 pandemic","volume":"5","author":"T\u00f6nnies","year":"2025","journal-title":"Front Epidemiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes\u20142024","volume":"47","author":"ElSayed","year":"2024","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.rec.2020.04.007","article-title":"2019 Esc guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and the European association for the study of diabetes (EASD)","volume":"73","author":"Cosentino","year":"2020","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.jacc.2018.07.081","article-title":"Blood sugar regulation as a key focus for cardiovascular health promotion and prevention: an umbrella review","volume":"72","author":"Schwarz","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1055\/a-1018-9106","article-title":"Therapy of type 2 diabetes","volume":"127","author":"Landgraf","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B9","year":"2021"},{"key":"B10","year":"2025"},{"key":"B11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.diabres.2018.09.002","article-title":"Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: results of the PDM-ProValue study program","volume":"144","author":"Kulzer","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B12","volume-title":"Digital Technology-Enabled Care Models for Diabetes: a Framework for Developing Quality Standards and Measures","year":"2023"},{"key":"B13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00125-019-05034-1","article-title":"Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European association for the study of diabetes (EASD) and the american diabetes association (ADA) diabetes technology working group","volume":"63","author":"Fleming","year":"2020","journal-title":"Diabetologia"},{"key":"B14","author":"Neuperdt","year":"2024"},{"key":"B15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1037\/hea0001037","article-title":"Associations of depression and diabetes distress with self-management behavior and glycemic control","volume":"40","author":"Schmitt","year":"2021","journal-title":"Health Psychol"},{"key":"B16","year":"2020"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e54324","DOI":"10.2196\/54324","article-title":"Effect of multimodal app-based interventions on glycemic control in patients with type 2 diabetes: systematic review and meta-analysis","volume":"27","author":"Bodner","year":"2025","journal-title":"J Med Internet Res"},{"key":"B18","volume-title":"Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus","year":"2012"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World medical association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"Association","year":"2013","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6317","DOI":"10.3390\/jcm12196317","article-title":"Effectiveness of a digital health application for the treatment of diabetes type II\u2014a pilot study","volume":"12","author":"Bretschneider","year":"2023","journal-title":"JCM"},{"key":"B21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00125-009-1559-5","article-title":"Short-form measures of diabetes-related emotional distress: the problem areas in diabetes scale (PAID)-5 and PAID-1","volume":"53","author":"McGuire","year":"2010","journal-title":"Diabetologia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e056304","DOI":"10.1136\/bmjopen-2021-056304","article-title":"Original research: how to identify clinically significant diabetes distress using the problem areas in diabetes (PAID) scale in adults with diabetes treated in primary or secondary care? Evidence for new cut points based on latent class analyses","volume":"12","author":"Wit","year":"2022","journal-title":"BMJ Open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2337\/dc10-1552","article-title":"Monitoring of individual needs in diabetes (MIND): baseline data from the cross-national diabetes attitudes, wishes, and needs (DAWN) MIND study","volume":"34","author":"Snoek","year":"2011","journal-title":"Diabetes Care"},{"key":"B24","author":"Beierlein","year":""},{"key":"B25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1026\/0012-1924\/a000205","article-title":"Normierung des SF-12 Version 2.0 zur Messung der gesundheitsbezogenen Lebensqualit\u00e4t in einer deutschen bev\u00f6lkerungsrepr\u00e4sentativen Stichprobe","volume":"64","author":"Wirtz","year":"2018","journal-title":"Diagnostica"},{"key":"B26","doi-asserted-by":"publisher","first-page":"P463","DOI":"10.1055\/s-0029-1238557","article-title":"Validierung des WHO-5 Wellbeing Index als Screeninginstrument f\u00fcr depressive St\u00f6rungen beim idiopathischen Parkinson-Syndrom","volume":"36","author":"Schneider","year":"2009","journal-title":"Akt Neurol"},{"key":"B27","first-page":"45","volume-title":"Wellbeing Measures in Primary Health Care\/the DepCare Project: Report on a WHO Meeting: Stockholm, Sweden, 12\u201313 February 1998","year":"1998"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.2337\/diacare.26.5.1641-a","article-title":"The diabetes empowerment scale-short form (DES-SF)","volume":"26","author":"Anderson","year":"2003","journal-title":"Diabetes Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12955-014-0185-1","article-title":"Assessing self-management in patients with diabetes mellitus type 2 in Germany: validation of a German version of the summary of diabetes self-care activities measure (SDSCA-G)","volume":"12","author":"Kamradt","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Validation and utility of a self-report version of PRIME-MDThe PHQ primary care study","volume":"282","author":"Spitzer","year":"1999","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3233\/ZMP-2003-12_2_08","article-title":"PHQ-D. Gesundheitsfragebogen f\u00fcr Patienten: 2. Auflage, Pfizer GmbH, Karlsruhe, 2002.","volume":"12","author":"L\u00f6we","year":"2003","journal-title":"Zeitschrift f\u00fcr Medizinische Psychologie"},{"key":"B32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e16791","DOI":"10.2196\/16791","article-title":"Mapping the evidence on the effectiveness of telemedicine interventions in diabetes, dyslipidemia, and hypertension: an umbrella review of systematic reviews and meta-analyses","volume":"22","author":"Timpel","year":"2020","journal-title":"J Med Internet Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1080\/10543406.2019.1684308","article-title":"A causal modelling framework for reference-based imputation and tipping point analysis in clinical trials with quantitative outcome","volume":"30","author":"White","year":"2020","journal-title":"J Biopharm Stat"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1080\/10543406.2013.834911","article-title":"Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation","volume":"23","author":"Carpenter","year":"2013","journal-title":"J Biopharm Stat"},{"key":"B36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/1536867X1601600211","article-title":"Reference-based sensitivity analysis via multiple imputation for longitudinal trials with protocol deviation","volume":"16","author":"Cro","year":"2016","journal-title":"Stata J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/hec.3963","article-title":"Reference-based multiple imputation for missing data sensitivity analyses in trial-based cost-effectiveness analysis","volume":"29","author":"Leurent","year":"2019","journal-title":"Health Econ"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1201\/9780429492259","volume-title":"Flexible Imputation of Missing Data","author":"vanBuuren","year":"2018"},{"key":"B39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Statist Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e68648","DOI":"10.2196\/68648","article-title":"Evaluation of the impact of Mobile health app vitadio in patients with type 2 diabetes: randomized controlled trial","volume":"27","author":"Bretschneider","year":"2025","journal-title":"J Med Internet Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3390\/nu16101510","article-title":"Comparing the efficacy of digital and in-person weight loss interventions for patients with obesity and glycemic disorders: evidence from a randomized non-inferiority trial","volume":"16","author":"Moravcov\u00e1","year":"2024","journal-title":"Nutrients"},{"key":"B42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41366-023-01415-0","article-title":"Efficacy of an app-based multimodal lifestyle intervention on body weight in persons with obesity: results from a randomized controlled trial","volume":"48","author":"Gemesi","year":"2024","journal-title":"Int J Obes"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/oby.23744","article-title":"A randomized-controlled trial to evaluate the app-based multimodal weight loss program zanadio for patients with obesity","volume":"31","author":"Roth","year":"2023","journal-title":"Obesity"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.zefq.2022.09.008","article-title":"Wie belastbar sind Studien der aktuell dauerhaft aufgenommenen digitalen Gesundheitsanwendungen (DiGA)? Methodische Qualit\u00e4t der Studien zum Nachweis positiver Versorgungseffekte von DiGA. Zeitschrift f\u00fcr Evidenz","volume":"175","author":"Kolominsky-Rabas","year":"2022","journal-title":"Fortbild Qual Gesundheitswes"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-022-08500-6","article-title":"Digital health applications and the fast-track pathway to public health coverage in Germany: challenges and opportunities based on first results","volume":"22","author":"Lantzsch","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"B46","year":"2025"},{"key":"B47","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/1742395319884096","article-title":"Clinical associations of an updated medication effect score for measuring diabetes treatment intensity","volume":"17","author":"Alexopoulos","year":"2019","journal-title":"Chronic Illn"}],"container-title":["Frontiers in Digital Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2025.1644612\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T06:36:08Z","timestamp":1765434968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2025.1644612\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":47,"alternative-id":["10.3389\/fdgth.2025.1644612"],"URL":"https:\/\/doi.org\/10.3389\/fdgth.2025.1644612","relation":{},"ISSN":["2673-253X"],"issn-type":[{"value":"2673-253X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"article-number":"1644612"}}